LUND, Sweden, March 30, 2020 /PRNewswire/ -- Immunovia invites
you to a teleconference (in English) for all stakeholders and media
on Wednesday, April 1, 2020 at
16:30 CET.
Mats Grahn, CEO will present an
update on the company's COVID-19 response as well as an update on
the activities in preparation for the Q3 2020 launch of IMMray™
PanCan-d and the prospective studies followed by a Q&A
session.
Please call in a few minutes in advance. To attend, please
dial-in at one of the numbers below and provide the conference code
Immunovia to the operator:
Conference Numbers:
Sweden: +46(0)8-50-520-424
Austria: +43(0)12530807
Germany:
+49(0)30-3001-90612
Denmark: +45-3271-4573
Switzerland:
+41(0)22-592-7103
Spain: +34-91-787-0777
Netherlands:
+31(0)20-794-8426
United States:
+1-212-999-6659
Norway: +47-2156-3318
France: +33(0)1-7037-7166
United Kingdom (standard
international access): +44(0)20-3003-2666
Conference Code: (to provide to the operator)
Immunovia
Immunovia Webcast:
https://channel.royalcast.com/webcast/immunovia/20200401_1/
There will be an MP3-file available at Immunovia's webpage under
Investors/Audio-Gallery
(https://immunovia.com/investors/audio-gallery/) for those who want
to listen to the telephone conference afterwards. The file will be
available within two hours after the conference has ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber
Director of Investor Relations
Immunovia Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-a-company-update-on-the-covid-19-response,c3076649
The following files are available for download:
https://mb.cision.com/Main/13121/3076649/1220729.pdf
|
Release
|